2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 3045

Immunometabolism in ANCA-Associated Glomerulonephritis
Abstract Number: 3046

Inflammatory Pathways As Shared Molecular Targets Across ANCA-Associated Vasculitis and Nephrotic Syndrome
Abstract Number: 3047

Diabetes and BMI Modify the Association Between Painful Hip OA and All-Cause Mortality
Abstract Number: 3048

Pain Severity As a Mediator of the Effect of Depressive Symptoms on Physical Performance in Knee Osteoarthritis
Abstract Number: 3049

Prevalence of Doctor-Diagnosed Arthritis Among Adults with Clinically Measured Pre-Diabetes— United States, 2009–2014
Abstract Number: 3050

Post-Partum Complications and Depression in New Mothers with Juvenile Arthritis
Abstract Number: 3051

Is Frailty a Relevant Concept in Systemic Lupus Erythematosus (SLE)?
Abstract Number: 3052

Causes of Death for Patients with Rheumatoid Arthritis
Abstract Number: 3053

Cartilage Loss Primarily Occurs in the Most Affected Tibiofemoral Compartment with No Evidence of a Ceiling Effect Among Advanced-Stage Disease: A Two-Year Longitudinal Study of Data from the Osteoarthritis
Abstract Number: 3054

The Impact of Obesity on Knee Osteoarthritis Symptoms and Related Biomarker Profiles in a Bariatric Surgery Cohort
Abstract Number: 3055

Ultrasound Features of the First Metatarsophalangeal Joint in Gout and Asymptomatic Hyperuricaemia: Comparison with Normouricaemic Individuals
Abstract Number: 3056

Efficacy of a Work Disability Prevention Program for People with Rheumatic and Musculoskeletal Conditions: A Randomized Controlled Trial
Abstract Number: 3057

Objectively Measured Physical Activity and Risk of Knee Osteoarthritis: The Osteoarthritis Initiative
Abstract Number: 3058

Varus Thrust and Incident and Progressive Knee Osteoarthritis
Abstract Number: 3059

Impact of a Musculoskeletal Training Program on Residents’ Evaluation, Diagnosis, and Treatment of Osteoporosis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].